Scott Avery, DO
Family Medicine · Junction City, KSNPI 1427230069
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,341 of the $195,086 with a category attached, or 84.8%. Teva Pharmaceuticals USA, Inc. accounts for 87.6% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $120,859, more than ten times the $205 reported in 2019. Among family medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $585.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$171K
- Otsuka America Pharmaceutical, Inc.$22K
- Neurocrine Biosciences, Inc.$1K
- Acadia Pharmaceuticals Inc$470
- Axsome Therapeutics, Inc.$243
- Otsuka Pharmaceutical Development & Commercialization, Inc.$198
- plus $278 from 4 others
What the payments were for
- Consulting fees$3950%
- Speaking & faculty fees$165,34185%
- Travel & lodging$20,35710%
- Food & beverage$8,6414%
- Education$3530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 248 | $170,862 |
| Otsuka America Pharmaceutical, Inc. | 38 | $21,887 |
| Neurocrine Biosciences, Inc. | 30 | $1,149 |
| Acadia Pharmaceuticals Inc | 8 | $470 |
| Axsome Therapeutics, Inc. | 2 | $243 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $198 |
| Smith+Nephew | 2 | $119 |
| Johnson & Johnson | 1 | $110 |
| SK Life Science, Inc. | 1 | $31 |
| Lundbeck LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$195,086 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 363 | $269,772 |
| EliquisApixaban | 804 | $237,669 |
| Austedo XrDeutetrabenazine | 38 | $217,154 |
| AustedoDeutetrabenazine | 41 | $163,344 |
| IngrezzaValbenazine Tosylate | 28 | $158,621 |
| NuplazidPimavanserin Tartrate | 47 | $122,029 |
| LinzessLinaclotide | 218 | $117,624 |
| Rivastigmine | 527 | $93,367 |
| Invega SustennaPaliperidone Palmitate | 31 | $90,135 |
| JardianceEmpagliflozin | 273 | $87,666 |
| XareltoRivaroxaban | 304 | $86,496 |
| UzedyRisperidone | 31 | $82,231 |
| JanuviaSitagliptin Phosphate | 255 | $72,327 |
| GemtesaVibegron | 247 | $62,133 |
| MyrbetriqMirabegron | 235 | $53,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $170,862 | $462,729110 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $21,887 | $269,772363 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $110 | $176,631335 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,149 | $158,62128 claims |
| Acadia Pharmaceuticals IncNuplazid | $470 | $122,02947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Junction City
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
- Hai TruongWichita$25K
- Deborah OutwaterWichita$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.